Gujarat Themis Biosyn completes acquisition of Japan's MicroBiopharm Japan for ₹475 Cr + ₹745 Cr loan
Gujarat Themis Biosyn Limited completed the acquisition of MicroBiopharm Japan Co., Ltd. through its subsidiary. The investment includes ₹475 Crore capital contribution and ₹745 Crore loan, with an additional ₹800 Crore loan facility. The deal aims to enhance fermentation capabilities and product portfolio.
The acquisition is a significant strategic move that will substantially enhance the company's capabilities, product offerings, and market presence, indicating a high impact on its future operations and growth.
The acquisition is expected to enhance the company's capabilities, expand its product portfolio, and broaden its geographical footprint, which are positive strategic developments.
Gujarat Themis Biosyn Limited (GTBL) has successfully completed the acquisition of MicroBiopharm Japan Co., Ltd. (MBJ), Japan, through its wholly-owned subsidiary, Themis Biosyn Japan Limited (TBJ).
The acquisition involved an investment of ₹475 Crores towards capital contribution and an additional ₹745 Crores by way of loan in TBJ. GTBL also entered into a loan agreement with TBJ for an amount up to ₹800 Crores.
All customary closing conditions, regulatory, and other formalities have been fulfilled. The transaction, initially announced on May 22, 2026, was funded through a mix of debt and equity for a total consideration of JPY 21.5 billion. MBJ, with over 60 years of experience, operates three GMP-compliant manufacturing plants and reported revenue of JPY 9.5 billion for FY26.
This acquisition is expected to enhance GTBL's fermentation capabilities, expand its product portfolio, and broaden its geographical footprint. It provides entry into precision fermentation, access to advanced biologics and novel modalities, and a scalable manufacturing footprint. The company anticipates the transaction to be EPS accretive. The existing MBJ management team will continue to lead operations.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.